Zurich Cantonal Bank
KIN

Zurich Cantonal Bank’s Kindred Biosciences, Inc. KIN Stock Holding History

Zurich Cantonal Bank’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,500
Closed -$102K – 2587
2017
Q1 		$102K Buy
+14,500
New +$90.8K ﹤0.01% 1348

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Zurich Cantonal Bank's KIN Position: Q2 2017 in Review

Zurich Cantonal Bank sold out of Kindred Biosciences, Inc. (KIN) in Q2 2017, closing a stake of 14,500 shares — an estimated $102K sold.

Zurich Cantonal Bank first reported a position in KIN in Q1 2017 and held it in 1 quarter. The position peaked at $102K in Q1 2017. 66 funds tracked by Wall St. Rank hold KIN as of Q2 2017.

  • Zurich Cantonal Bank reported no remaining Kindred Biosciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • Zurich Cantonal Bank sold 14,500 Kindred Biosciences, Inc. shares in Q2 2017, an estimated $102K.
  • Zurich Cantonal Bank first reported a position in Kindred Biosciences, Inc. in Q1 2017 and held it in 1 quarter.
  • Zurich Cantonal Bank's Kindred Biosciences, Inc. position peaked at $102K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2017.

Based on Zurich Cantonal Bank's 13F filing for Q2 2017, filed 8 Aug 2017.